Hirsch Yonatan, Geraghty Joseph R, Katz Eitan A, Testai Fernando D
Department of Neurology and Rehabilitation, College of Medicine, University of Illinois at Chicago, 912 S. Wood St. Suite 174 N, Chicago, IL, 60612, USA.
Medical Scientist Training Program, University of Illinois at Chicago, Chicago, IL, USA.
Neurocrit Care. 2021 Jun;34(3):889-898. doi: 10.1007/s12028-020-01113-z. Epub 2020 Sep 30.
BACKGROUND/OBJECTIVE: Subarachnoid hemorrhage (SAH) is a devastating neurological injury, further complicated by few available methods to objectively predict outcomes. With the recent shift in focus to neuroinflammation as a potential cause of adverse outcomes following SAH, we investigated the inflammasome-derived enzyme, caspase-1, as a potential biomarker for poor functional outcome.
SAH patients were recruited from a regional stroke referral center. Cerebrospinal fluid (CSF) samples from 18 SAH subjects were collected via an external ventricular drain and obtained as close as possible to admission (within 72 h). For control subjects, we collected CSF from 9 patients undergoing lumbar puncture with normal CSF. Caspase-1 activity was measured using commercially available luminescence assays. SAH subjects were categorized at hospital discharge into those with good outcomes (Glasgow Outcome Scale, GOS, of 4-5) and poor outcomes (GOS of 1-3).
CSF analysis demonstrated a nearly seven-fold increase in caspase-1 activity in SAH patients compared to controls (p < 0.0001). Within the SAH group, 10 patients (55.6%) had good outcomes and 8 patients (44.4%) had poor outcomes. Mean caspase-1 activity in the poor outcome group was approximately three-times higher than the good outcome group (p = 0.001). Caspase-1 activity was significantly correlated with GOS score (r = - 0.705, p = 0.001). Receiver operating characteristic curve analysis showed that caspase-1 activity can accurately differentiate between patients with good versus poor functional outcome (area under the curve 0.944, p = 0.002).
Inflammasome-derived caspase-1 activity is elevated in the CSF of SAH patients compared to controls and higher levels correlate with worse functional outcome.
背景/目的:蛛网膜下腔出血(SAH)是一种严重的神经损伤,由于缺乏客观预测预后的方法,病情进一步复杂化。随着最近研究重点转向神经炎症作为SAH后不良预后的潜在原因,我们研究了炎性小体衍生酶半胱天冬酶-1作为功能预后不良的潜在生物标志物。
SAH患者从一个地区性中风转诊中心招募。通过外部脑室引流管收集18例SAH患者的脑脊液(CSF)样本,并在入院后尽可能接近的时间(72小时内)获取。对于对照受试者,我们从9例脑脊液正常的腰椎穿刺患者中收集脑脊液。使用市售的发光测定法测量半胱天冬酶-1的活性。SAH患者在出院时分为预后良好(格拉斯哥预后评分,GOS,4-5分)和预后不良(GOS,1-3分)两组。
脑脊液分析显示,与对照组相比,SAH患者的半胱天冬酶-1活性增加了近7倍(p<0.0001)。在SAH组中,10例患者(55.6%)预后良好,8例患者(44.4%)预后不良。预后不良组的平均半胱天冬酶-1活性比预后良好组高约3倍(p=0.001)。半胱天冬酶-1活性与GOS评分显著相关(r=-0.705,p=0.001)。受试者工作特征曲线分析表明,半胱天冬酶-1活性可以准确区分功能预后良好和不良的患者(曲线下面积0.944,p=0.002)。
与对照组相比,SAH患者脑脊液中炎性小体衍生的半胱天冬酶-1活性升高,且较高水平与较差的功能预后相关。